Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PRO MEDICUS LIMITED Director's Dealing 2016

Nov 22, 2016

65579_rns_2016-11-22_97a638eb-cdb4-4f85-929f-1f86e6e92527.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Listing Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Pro Medicus Limited ABN 25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Roderick Lyle
Date of last notice 23 August 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Ordinary fully paid shares in Pro Medicus
Limited held by Roderick Lyle
Date of change 23 November 2016
No. of securities held prior to change 300,000 ordinary shares consisting off:-

160,000 ordinary shares held under
Roderick LYLE

140,000 ordinary shares held under
Radling Pty Ltd: Trustee of the Lyle
Superannuation Fund of which the
Director is a Trustee and Member
40,000ordinaryshare options
Class Ordinary shares
Number acquired 40,000
Number disposed Nil
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration $0.55 cents per share – exercise of share $0.55 cents per share – exercise of share
Note: If consideration is non-cash, provide details and estimated valuation options
No. of securities held after change 340,000 ordinary shares consisting off:-
200,000 ordinary shares held under
Roderick LYLE
140,000 ordinary shares held under
Radling Pty Ltd: Trustee of the Lyle
Superannuation Fund of which the
Director is a Trustee and Member
Nature of change Exercise of share options - $0.55 per share
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder N/A
(if issued securities)
Date of change N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

If If g g g g g g g
If o was prior w ritten cleara nce provided to allow the N/A

tra
,
de to proceed d

uring this p

eriod?
If p
rior written cle
arance was provided, on w hat date was N/A
this provided?

For and on behalf of Pro Medicus Limited

==> picture [133 x 63] intentionally omitted <==

Clayton Hatch Company Secretary 23 November 2016

  • See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002